Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

Mehta said HUL's focus would continue to ensure uninterrupted supplies of COVID relevant portfolio and meeting the demand arising out of evolving consumer needs ...

The US Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups.

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...

GSK CEO Emma Walmsley's bet on blockbuster RSV vaccine, Arexvy, has hit a snag in recent months after the U.S. public health agency narrowed the age recommendation for use of RSV vaccines and ...

Haleon backed its full-year guidance despite lower third-quarter revenue and earnings, although organic revenue growth of 6.1% topped its own forecasts.

Phenylephrine:CVS pulls cold medicines with the ingredient Companies such as Procter & Gamble and GSK were among several accused ... or remove such drugs from the market. The Consumer Healthcare ...

Bernstein analyst Justin Smith maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

Editorial Note: Blueprint may earn a commission from affiliate partner links featured here on our site. This commission does not influence our editors' opinions or evaluations. Please view our ...